Friday, October 30, 2026

Planet Labs deploys Google TPU satellites in early 2027, merging space tech with cloud AI compute

Planet Labs plans to launch two SunCatcher prototype satellites with Google TPUs in early 2027, funded through a Google R&D partnership. The orbital AI compute project emerges as Planet posted $81.3M Q3 revenue (+33% YoY) and $734.5M backlog, driven by 70% growth in defense contracts.

Source Trace Score1 source document1 with a live linkVerifiability: Basic
Planet Labs deploys Google TPU satellites in early 2027, merging space tech with cloud AI compute
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

Planet Labs will deploy two SunCatcher prototype satellites equipped with Google Tensor Processing Units in early 2027, according to the company's Q3 2026 earnings call. Google is funding the R&D program through a partnership with Planet's Gemini collaboration team.

The orbital AI compute initiative represents a new convergence point between satellite operators and cloud infrastructure providers. Planet CEO Will Marshall disclosed the SunCatcher project alongside record Q3 financial performance: $81.3M revenue (up 33% year-over-year) and $5.6M adjusted EBITDA, the company's fourth consecutive profitable quarter.

Planet's backlog reached $734.5M, up 216% year-over-year, with defense and intelligence contracts growing 70%. The company secured $12.8M from the National Geospatial-Intelligence Agency for AI-driven maritime analytics and renewed its $21.1M annual NRO contract, which now includes framework provisions for high-resolution Pelican satellite imagery.

The SunCatcher prototypes will test whether satellite-based AI processing can deliver value beyond traditional ground-station compute architectures. Planet already committed to NVIDIA GPUs for its Owl constellation, a next-generation 1-meter monitoring fleet scheduled for late 2026 tech demonstrations. The Google TPU partnership adds a competing approach using tensor-specific chips designed for machine learning workloads.

Planet raised $460M in convertible notes at 0.5% interest during Q3, maintaining $677M cash position. The company projects $297-301M revenue for fiscal 2026 with positive annual free cash flow. CapEx guidance of $81-85M includes hardware prepayments and launch deposits for the expanding satellite fleet.

Defense sector momentum contrasts with commercial segment declines reported quarter-over-quarter. Planet closed its acquisition of Bedrock Research, a Denver-based AI firm specializing in remote sensing for national security applications, strengthening in-house capabilities for government contracts.

The company operates five commercial Pelican satellites and targets 30-satellite deployment for 30-minute latency and 30 daily revisits. Planet has launched over 600 satellites to date, including 36 Super Dove satellites commissioned in Q3 that achieved first light within 24 hours.

Source documents

Via News is a conduit. We point to the source documents behind this report — we don't replace them. Trace any claim to its source and decide what to trust. How we source

Source Trace Score1 source document1 with a live linkVerifiability: Basic
  1. [1]Earnings callNasdaq· December 11, 2025
    Planet Labs (PL) Q3 2026 Earnings Call Transcript
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com